triangle

Partnering

Partnering Opportunities

Serimmune partners with academic institutions as well as biopharma and healthcare organizations that seek to better understand the antibody-epitope repertoire to empower immune-related research, product development, and healthcare decision-making.

triangles

BIOMARKER DISCOVERY

Autoimmune Disease

SERA has been used to identify both validated and potentially novel antigens in multiple autoimmune disorders1. Candidate autoantigens in cohorts may help distinguish sub-types of disease or help to predict/track response to therapy, identify new targets, and enable precision immunology.

Oncology

Using SERA, researchers can identify candidate autoantigens that may be used as biomarkers for diagnosis, sub-typing, or monitoring in oncology2. B cell response in immuno-oncology has recently been highlighted in association with response to checkpoint inhibitor therapy3. SERA enables the tracking of potential autoantigen signals before and after therapy to identify candidate biomarkers of response to therapy, paving the way for precision oncology.

Infectious Disease

SERA can identify the most significant antigens in infections for diagnostic and therapeutic target discovery as demonstrated in COVID-194. Using cohorts with disease, SERA can also identify sensitive and specific peptides for infections that can be used on alternate diagnostic platforms.

Therapeutics

SERA is a powerful tool that pharmaceutical and biotech organizations can leverage for identification of motifs and peptide epitopes recognized by monoclonal antibodies. These can be used to optimize the selection of therapeutic candidates5. SERA has also identified the antigenic targets of antibody repertoires to identify therapeutic targets. This screening may identify potential off-target antigens for our partners.

Population Serosurveillance

SERA has the broad potential to enable dynamic monitoring and surveillance for hundreds of diseases in one assay. It has recently been used to demonstrate the increase in seropositivity early in the COVID-19 epidemic. Significantly, SERA has also demonstrated the ability to detect seropositivity retrospectively and in silico, without the need of any new assays6, enabling serosurveillance in individuals and populations for a variety of emerging infections.

OTHER AREAS OF INTEREST FOR PARTNERING INCLUDE:

  • Custom diagnostic panel content development in infectious disease
  • Identification of antibody biomarkers for early disease detection
  • Identification of antibody biomarkers for monitoring disease
Partner With Us